The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Isoquinolines binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Isoquinolines affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [Isoquinolines results in increased activity of DRD1 protein]
Isoquinolines analog binds to and results in decreased activity of HPGDS protein; Water affects the reaction [Isoquinolines analog binds to and results in decreased activity of HPGDS protein]
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]
BCL2 protein affects the susceptibility to tetrandrine tetrandrine results in increased expression of BCL2 protein CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein] tetrandrine results in decreased expression of BCL2 mRNA; tetrandrine results in decreased expression of BCL2 protein
tetrandrine results in increased expression of BECN1 protein [sodium arsenite co-treated with tetrandrine] results in increased expression of BECN1 protein tetrandrine results in decreased expression of BECN1 protein
tetrandrine results in increased expression of CASP3 protein tetrandrine results in increased cleavage of CASP3 protein 3-methyladenine inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]; tetrandrine results in increased cleavage of and results in increased activity of CASP3 protein
tetrandrine results in increased cleavage of and results in increased activity of CASP8 protein tetrandrine results in increased expression of CASP8 protein tetrandrine results in increased cleavage of CASP8 protein
tetrandrine results in increased cleavage of and results in increased activity of CASP9 protein tetrandrine results in increased cleavage of CASP9 protein
[sodium arsenite co-treated with tetrandrine] affects the expression of CCND1 protein; [sodium arsenite co-treated with tetrandrine] results in decreased expression of CCND1 protein tetrandrine results in decreased expression of CCND1 protein tetrandrine affects the expression of CCND1 protein
tetrandrine results in increased expression of CDKN1A tetrandrine affects the expression of CDKN1A protein [sodium arsenite co-treated with tetrandrine] affects the expression of CDKN1A protein
[sodium arsenite co-treated with tetrandrine] results in increased expression of CDKN1B protein tetrandrine results in increased expression of CDKN1B protein
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]
[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; [tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IFNG protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL6 protein]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]
[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA; [tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein; AHR protein affects the reaction [tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein]; AHR protein affects the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 mRNA]; Dactinomycin inhibits the reaction [tetrandrine results in increased expression of CYP1A1 protein]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 mRNA]; Resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of CYP1A1 protein]; tetrandrine results in increased expression of and results in increased activity of CYP1A1 protein
CYP3A5 protein results in increased glutathionylation of tetrandrine CYP3A5 protein results in increased susceptibility to tetrandrine CYP3A5 protein promotes the reaction [tetrandrine results in decreased abundance of Glutathione]; CYP3A5 protein promotes the reaction [tetrandrine results in decreased expression of BCL2 protein]; CYP3A5 protein promotes the reaction [tetrandrine results in increased abundance of Reactive Oxygen Species]; CYP3A5 protein promotes the reaction [tetrandrine results in increased expression of CASP3 protein]
[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of FOXO3 protein; [sodium arsenite co-treated with tetrandrine] results in increased expression of FOXO3 protein; tetrandrine affects the expression of and affects the phosphorylation of FOXO3 protein
[tetrandrine co-treated with COL2A1 protein] results in increased expression of FOXP3 mRNA; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]; resveratrol inhibits the reaction [tetrandrine results in increased expression of FOXP3 mRNA]
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] tetrandrine results in increased expression of ICAM1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [[arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tetrandrine results in increased expression of ICAM1 protein]; [arsenite co-treated with tetrandrine] affects the expression of ICAM1 protein; [arsenite co-treated with tetrandrine] results in increased expression of ICAM1 protein
[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein; alpha-naphthoflavone inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]; resveratrol inhibits the reaction [[tetrandrine co-treated with COL2A1 protein] results in increased expression of IL10 protein]; resveratrol inhibits the reaction [tetrandrine results in increased expression of IL10 mRNA]
resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein] tetrandrine results in decreased expression of IL17A mRNA
tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of CHUK protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein] tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL1B protein]
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein] tetrandrine results in increased phosphorylation of MAPK1 protein [arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK1 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK1 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK1 protein]
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein] tetrandrine results in increased phosphorylation of MAPK3 protein [arsenite co-treated with tetrandrine] results in increased phosphorylation of MAPK3 protein; arsenite promotes the reaction [tetrandrine results in increased phosphorylation of MAPK3 protein]; tetrandrine promotes the reaction [arsenite results in increased phosphorylation of MAPK3 protein]
tetrandrine inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of MMP9 protein] tetrandrine results in decreased expression of MMP9 protein
[sodium arsenite co-treated with tetrandrine] affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine affects the expression of and affects the phosphorylation of MTOR protein; tetrandrine results in decreased expression of and results in decreased phosphorylation of MTOR protein tetrandrine results in decreased expression of MTOR protein; tetrandrine results in decreased expression of MTOR protein modified form
tetrandrine inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein] tetrandrine results in decreased expression of and results in decreased activity of RELA protein tetrandrine results in increased phosphorylation of RELA protein
tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of RORC mRNA] tetrandrine results in decreased expression of RORC mRNA
tetrandrine inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; tetrandrine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
tetrandrine inhibits the reaction [TNF protein results in increased expression of CHUK protein]; tetrandrine inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; tetrandrine inhibits the reaction [TNF protein results in increased localization of RELA protein]; tetrandrine inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]]; tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of TNF protein]
salsolinol results in increased activity of CASP3 protein salsolinol results in increased cleavage of CASP3 protein Memantine inhibits the reaction [salsolinol results in increased activity of CASP3 protein]
1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA mRNA; 1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]; Acetylcysteine inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]; coenzyme Q10 inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]; Selegiline inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCB4 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of ABCC3 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of AVPR1A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of BHMT mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CCNG1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CD36 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CDC14B mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CEMIP2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of CXCL12 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of CYP1A2 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of FASN mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GCLC mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of GSR mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of LPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of LSS mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR101A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] affects the expression of MIR122 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of MIR192 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of NQO1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of PLA2G12A mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of SCD1 mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in decreased expression of THRSP mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of TXNRD1 mRNA
1,2,3,4-tetrahydroisoquinoline results in decreased expression of IL6 mRNA IL6 protein results in decreased susceptibility to 1,2,3,4-tetrahydroisoquinoline
1,2,3,4-tetrahydroisoquinoline analog results in decreased activity of MAOB protein; 1,2,3,4-tetrahydroisoquinoline results in decreased activity of MAOB protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1A mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1D mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Ouabain results in increased expression of ATP1B1 mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased expression of ATP1B1 mRNA
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT1 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT3 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]
[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with Doxorubicin] results in increased expression of EP300 protein 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in increased expression of EP300 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin results in increased expression of FOS mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of FOS mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lead results in increased expression of FOS mRNA]
[SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [jasplakinolide results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [latrunculin B results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GDF15 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ICAM1 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of JUN mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Paraquat results in increased expression of JUN mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [5,8,11,14-Eicosatetraynoic Acid analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [ciprofibrate analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Clofibrate results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [pirinixic acid results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Thapsigargin analog results in increased expression of JUNB mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K1 protein [1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein
[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K2 protein 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K2 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Heptachlor affects the localization of PRKCA protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Heptachlor affects the localization of PRKCD protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCD protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Cadmium Chloride results in increased expression of SLC30A1 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Zinc Sulfate results in increased expression of SLC30A1 mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT1 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT3 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TGFB1 protein results in increased expression of RARA mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased activity of TGFB1 protein
[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein; [1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K2 protein; [TNF protein co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] results in increased activity of NFKB protein 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TNF protein results in increased expression of AQP4 mRNA]
Praziquantel results in increased activity of TRPM8 protein TRPM8 gene mutant form results in decreased susceptibility to Praziquantel Calcium deficiency inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; Menthol inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; N-(3-aminopropyl)-2-(((3-methylphenyl) methyl)oxy)-N-(2-thienylmethyl)benzamide hydrochloride salt inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; Praziquantel inhibits the reaction [Menthol results in increased activity of TRPM8 protein]
Praziquantel results in decreased expression of VEGFA mRNA; Praziquantel results in decreased expression of VEGFA protein [Resveratrol co-treated with Praziquantel] results in decreased expression of VEGFA mRNA; [Resveratrol co-treated with Praziquantel] results in decreased expression of VEGFA protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1A mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [AGT protein results in increased expression of ADRA1D mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased expression of ATP1B1 mRNA 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Ouabain results in increased expression of ATP1B1 mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT1 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT3 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP1A1 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 mRNA]
[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with Doxorubicin] results in increased expression of EP300 protein 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in increased expression of EP300 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of FOS mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lead results in increased expression of FOS mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin results in increased expression of FOS mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]
[SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [jasplakinolide results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [latrunculin B results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GDF15 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ICAM1 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Acetaldehyde results in increased expression of JUN mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Paraquat results in increased expression of JUN mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [5,8,11,14-Eicosatetraynoic Acid analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Calcimycin results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [ciprofibrate analog results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Clofibrate results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [pirinixic acid results in increased expression of JUNB mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Thapsigargin analog results in increased expression of JUNB mRNA]
[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K1 protein
[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K2 protein 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased phosphorylation of MAP2K2 protein
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Heptachlor affects the localization of PRKCA protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCA protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Heptachlor affects the localization of PRKCD protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PRKCD protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 protein]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Cadmium Chloride results in increased expression of SLC30A1 mRNA]; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Zinc Sulfate results in increased expression of SLC30A1 mRNA]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT1 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [CNTF protein affects the phosphorylation of and affects the activity of STAT3 protein]
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TGFB1 protein results in increased expression of RARA mRNA] 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine results in decreased activity of TGFB1 protein
[1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K1 protein; [1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine co-treated with TNF protein] results in decreased phosphorylation of MAP2K2 protein; [TNF protein co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] results in increased activity of NFKB protein 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [TNF protein results in increased expression of AQP4 mRNA]
Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form] Bicuculline results in decreased expression of GABRA1 mRNA
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]
Bicuculline inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB1 protein]] Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]
Bicuculline results in decreased expression of GABRB3 mRNA Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]
Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]]; Bicuculline inhibits the reaction [methylmercuric chloride promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]] Bicuculline promotes the reaction [tetramethylenedisulfotetramine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein alternative form]]]; Bicuculline results in decreased activity of [GABRA1 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA2 protein binds to GABRB3 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB1 binds to GABRG2 protein alternative form]; Bicuculline results in decreased activity of [GABRA6 protein binds to GABRB3 binds to GABRG2 protein alternative form]
Bicuculline affects the reaction [bisphenol A affects the secretion of GNRH1 protein]; Bicuculline promotes the reaction [manganese chloride results in increased secretion of GNRH1 protein]
Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; Bicuculline results in decreased expression of and results in decreased localization of GRIA2 protein; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline results in decreased expression of GRIA2 mRNA; Bicuculline results in decreased expression of GRIA2 protein
Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK1 protein] [Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein]
Bicuculline inhibits the reaction [methyl tert-butyl ether results in decreased phosphorylation of MAPK3 protein] [Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein]
MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline promotes the reaction [MECP2 protein binds to GRIA2 promoter]; MECP2 protein affects the reaction [Bicuculline results in decreased expression of GRIA2 protein] Bicuculline results in increased phosphorylation of MECP2 protein Bicuculline results in increased expression of MECP2 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]
Bicuculline inhibits the reaction [Propofol inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]; Bicuculline inhibits the reaction [Thiopental inhibits the reaction [Vincristine results in decreased susceptibility to NGF protein]]
[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]
Bicuculline promotes the reaction [Reserpine affects the activity of TH protein]; Bicuculline promotes the reaction [Reserpine results in increased expression of TH mRNA]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased activity of GPT protein]]; corynoline inhibits the reaction [Zearalenone results in increased activity of GPT protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline promotes the reaction [Zearalenone results in increased expression of HMOX1 protein]]; corynoline promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; corynoline promotes the reaction [Zearalenone results in increased expression of HMOX1 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased expression of IL1B protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; corynoline inhibits the reaction [Zearalenone results in increased expression of IL1B protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased activity of MPO protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of MPO protein]; corynoline inhibits the reaction [Zearalenone results in increased activity of MPO protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline promotes the reaction [Zearalenone results in increased expression of NFE2L2 protein]]; corynoline promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NFE2L2 protein]; corynoline promotes the reaction [Zearalenone results in increased expression of NFE2L2 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of NFKBIA protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein]; corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of NFKBIA protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of RELA protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]; corynoline inhibits the reaction [Zearalenone results in increased phosphorylation of RELA protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in decreased expression of SIRT1 protein]]; corynoline inhibits the reaction [Zearalenone results in decreased expression of SIRT1 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [corynoline inhibits the reaction [Zearalenone results in increased expression of TNF protein]]; corynoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; corynoline inhibits the reaction [Zearalenone results in increased expression of TNF protein]
CYP3A4 protein results in increased glutathionylation of dauricine [CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of N-desmethyldauricine; [CYP3A4 protein results in increased glutathionylation of dauricine] which results in increased chemical synthesis of quinone methide; CYP3A4 protein results in increased oxidation of and results in increased activity of dauricine; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased glutathionylation of dauricine]
CYP2D6 gene mutant form affects the metabolism of and affects the hydroxylation of Debrisoquin; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in decreased susceptibility to Debrisoquin]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in increased abundance of Debrisoquin metabolite] CYP2D6 protein results in increased metabolism of Debrisoquin CYP2D6 protein results in increased hydroxylation of Debrisoquin CYP2D6 protein affects the metabolism of Debrisoquin; CYP2D6 protein polymorphism affects the metabolism of Debrisoquin CYP2D6 gene mutant form results in decreased metabolism of Debrisoquin; CYP2D6 gene polymorphism results in decreased metabolism of Debrisoquin
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK1 protein] MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]
Emetine results in increased phosphorylation of and results in increased activity of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein]
Emetine results in increased phosphorylation of MAPK3 protein Emetine results in decreased phosphorylation of MAPK3 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein] 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK3 protein]
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK8 protein]
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK9 protein]
Emetine results in decreased activity of MMP2 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein] Emetine results in decreased expression of MMP2 mRNA
Emetine results in decreased activity of MMP9 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein] Emetine results in decreased expression of MMP9 mRNA
fasudil inhibits the reaction [Paraquat results in increased expression of BAX mRNA]; fasudil inhibits the reaction [Streptozocin results in increased expression of BAX protein]
fasudil inhibits the reaction [Paraquat results in decreased expression of BCL2 mRNA]; fasudil inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein] fasudil results in increased expression of BCL2 protein
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein
fasudil inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; fasudil inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA]
fasudil results in decreased expression of CFL1 mRNA fasudil inhibits the reaction [Streptozocin results in increased phosphorylation of CFL1 protein] fasudil results in decreased expression of and results in decreased phosphorylation of CFL1 protein
fasudil results in decreased expression of COL1A1 mRNA 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA
fasudil inhibits the reaction [Methylmercury Compounds results in increased expression of IL1B protein]; fasudil inhibits the reaction [Paraquat results in increased expression of IL1B protein] fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein]; fasudil inhibits the reaction [Paraquat results in increased secretion of IL1B protein] fasudil inhibits the reaction [Acetaminophen results in increased expression of IL1B protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein]
fasudil inhibits the reaction [Methylmercury Compounds results in increased expression of IL6 protein]; fasudil inhibits the reaction [Paraquat results in increased expression of IL6 protein] fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]; fasudil inhibits the reaction [Paraquat results in increased secretion of IL6 protein] fasudil inhibits the reaction [Acetaminophen results in increased expression of IL6 protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]
fasudil inhibits the reaction [Streptozocin results in decreased expression of NFKBIA protein] fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of NFKBIA protein]
fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]; fasudil inhibits the reaction [Paraquat results in increased phosphorylation of PPP1R12A protein]; fasudil inhibits the reaction [Streptozocin results in increased expression of PPP1R12A protein modified form]
fasudil inhibits the reaction [Methylmercury Compounds results in increased phosphorylation of RELA protein]; fasudil inhibits the reaction [Streptozocin results in increased expression of and affects the localization of RELA protein] fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of RELA protein]
fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RHO mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RHO protein] fasudil inhibits the reaction [Paraquat results in increased expression of RHO protein] fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RHO mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of RHO protein]; fasudil inhibits the reaction [Paraquat results in increased expression of RHO protein]
fasudil results in decreased expression of RHOA mRNA; fasudil results in decreased expression of RHOA protein fasudil inhibits the reaction [Acetaminophen results in increased expression of RHOA protein]
fasudil results in decreased expression of ROCK1 mRNA; fasudil results in decreased expression of ROCK1 protein fasudil inhibits the reaction [Acetaminophen results in increased expression of ROCK1 protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK1 mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK1 protein] fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK1 mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK1 protein]; fasudil inhibits the reaction [Paraquat results in increased expression of ROCK1 protein] fasudil affects the reaction [Daunorubicin affects the expression of ROCK1 mRNA]; fasudil inhibits the reaction [Paraquat results in increased expression of ROCK1 protein]; fasudil inhibits the reaction [Streptozocin results in increased activity of ROCK1 protein]; fasudil inhibits the reaction [Streptozocin results in increased expression of ROCK1 mRNA]
fasudil results in decreased activity of ROCK2 protein fasudil inhibits the reaction [Acetaminophen results in increased expression of ROCK2 protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK2 mRNA]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ROCK2 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein
fasudil inhibits the reaction [Rotenone results in decreased expression of SYP mRNA]; fasudil inhibits the reaction [Streptozocin results in decreased expression of SYP mRNA]; fasudil inhibits the reaction [Streptozocin results in decreased expression of SYP protein]
fasudil affects the expression of TNF mRNA fasudil inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein] fasudil inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; fasudil inhibits the reaction [Paraquat results in increased secretion of TNF protein] fasudil inhibits the reaction [Methylmercury Compounds results in increased expression of TNF protein]; fasudil inhibits the reaction [Paraquat results in increased expression of TNF protein]
isoliensinine results in decreased phosphorylation of AKT1 protein isoliensinine promotes the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein]
isoliensinine results in decreased expression of BCL2 mRNA; isoliensinine results in decreased expression of BCL2 protein isoliensinine inhibits the reaction [RELA protein binds to BCL2 promoter] isoliensinine affects the expression of BCL2 protein
isoliensinine inhibits the reaction [RELA protein binds to BCL2L1 promoter] isoliensinine results in decreased expression of BCL2L1 mRNA; isoliensinine results in decreased expression of BCL2L1 protein
isoliensinine results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [isoliensinine results in increased cleavage of CASP3 protein]; RELA protein mutant form inhibits the reaction [isoliensinine results in increased activity of CASP3 protein]
isoliensinine results in increased phosphorylation of MAPK8 protein Acetylcysteine inhibits the reaction [isoliensinine results in increased phosphorylation of MAPK8 protein]
isoliensinine results in increased cleavage of PARP1 protein Acetylcysteine inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]
isoliensinine results in decreased phosphorylation of RELA protein isoliensinine inhibits the reaction [RELA protein binds to BCL2 promoter]; isoliensinine inhibits the reaction [RELA protein binds to BCL2L1 promoter]; RELA protein mutant form inhibits the reaction [isoliensinine results in increased activity of CASP3 protein]
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of and results in increased acetylation of HMGB1 protein]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of HMGB1 protein]
1,5-dihydroxyisoquinoline inhibits the reaction [Vancomycin results in increased expression of PARP1 protein] 1,5-dihydroxyisoquinoline results in decreased expression of PARP1 protein 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]] 1,5-dihydroxyisoquinoline results in decreased activity of PARP1 protein
1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [PARP1 protein binds to SIRT1 protein]]; 1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]
BCHE affects the susceptibility to mivacurium; BCHE gene polymorphism affects the susceptibility to mivacurium; BCHE protein affects the susceptibility to mivacurium BCHE gene mutant form results in increased susceptibility to mivacurium
mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]
mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; mivacurium inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]
N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide affects the localization of and results in increased cleavage of and results in increased activity of CASP8 protein
N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide promotes the reaction [TNFSF10 protein results in increased expression of BIRC2 protein]; N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide promotes the reaction [TNFSF10 protein results in increased expression of XIAP protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of ABCB1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of ABCB1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Taurolithocholic Acid results in decreased activity of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADORA2B protein inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]
SB 203580 inhibits the reaction [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the phosphorylation of AKT1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of AKT1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of APOE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of CETP mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of APOE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of CETP protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased expression of APOE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [APOA1 protein results in increased secretion of APOE protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [VIP protein results in increased expression of AQP3 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of ATF3 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of ATF3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the localization of and results in decreased phosphorylation of BAD protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [BAD protein binds to BCL2L1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of BAD protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [cordycepin results in increased expression of BMP4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of BMP4 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased cleavage of CASP3 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased cleavage of CASP3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased expression of CCND1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD86 mRNA]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPB mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Octanol results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [tetramethylpyrazine results in increased activity of CFTR protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of CFTR protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CFTR protein affects the transport of Water] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the localization of CFTR protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CGA protein results in increased cleavage of SREBF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CGA protein results in increased cleavage of SREBF2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of CHI3L3 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [bisphenol A results in increased phosphorylation of and results in increased activity of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [cordycepin results in increased expression of CREB1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of CREB1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein promotes the reaction [Testosterone results in increased phosphorylation of CREB1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Roflumilast promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]] [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(3-3,4-p-menthadien-(1,8)-yl)olivetol results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [alternariol results in increased expression of CREB1 protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [O-1602 compound results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in decreased expression of CREB1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Sodium Oxybate results in increased phosphorylation of CREBBP protein]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride affects the localization of CTNNB1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [3',4'-dimethoxyflavone results in increased expression of CYP11B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of CYP11B1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP19A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Water Pollutants, Chemical analog results in increased expression of CYP19A1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [bisphenol A results in increased expression of and results in increased activity of CYP19A1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TNF protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of EGR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin results in increased expression of EGR1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin results in increased expression of EGR1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD68 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1,1-dimethylbutyl-1-deoxy-Delta(9)-THC inhibits the reaction [F2 protein results in increased expression of CD86 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of CHI3L3 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dieldrin results in increased expression of FOS mRNA] [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOS mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOSL1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of FOSL1 mRNA]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of FOSL2 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Estradiol]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Progesterone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased secretion of Progesterone] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein promotes the reaction [Testosterone results in increased phosphorylation of CREB1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased phosphorylation of TSC2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased expression of MYC mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GCG protein results in increased phosphorylation of CTNNB1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Acetaminophen results in decreased expression of and results in decreased activity of GPX1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [roflupram inhibits the reaction [Copper Sulfate results in decreased expression of GPX1 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of GRIN1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased expression of GSDMD mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased expression of GSDMD protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of HAS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of HAS2 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of HMOX1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ferric ammonium citrate results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [hexacyanoferrate III results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of HSD11B1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Iloprost results in increased expression of ID1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IKBKB mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Histamine results in increased expression of IL18 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased secretion of IL18 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ammonia results in increased secretion of IL1B protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of IL1B mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in increased secretion of IL1B protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased secretion of IL4 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL4 mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL5 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased secretion of IL5 protein
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of PLIN2 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PLIN1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARGC1A protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of UCP1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IRS1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2-(2-fluorobenzamido)benzoate ethyl ester inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of JUN mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of JUN mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with U 0126] inhibits the reaction [Isoproterenol results in increased expression of JUNB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased expression of JUNB mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased activity of [KCNQ1 protein binds to KCNE1 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased activity of [KCNQ1 protein binds to KCNE1 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [KNG1 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased chemical synthesis of Reactive Oxygen Species]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CCL2]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased susceptibility to LEP protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of CEBPB mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of HAS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PGR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PTGS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of TNFAIP6 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased expression of AREG protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased secretion of Progesterone]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein modified form]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Thioctic Acid results in increased phosphorylation of LIPE protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK1 protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Levodopa results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADM protein results in decreased activity of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK1 protein modified form]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in increased phosphorylation of and results in increased activity of MAPK1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Levodopa results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [1-Methyl-3-isobutylxanthine promotes the reaction [FSHB protein inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nitroprusside results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Quercetin promotes the reaction [Glucose results in increased expression of MAPK3 protein modified form]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Ro 31-8425 inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Ro 31-8425 promotes the reaction [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Capsaicin results in increased phosphorylation of MAPK3 protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[GPER1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK3 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin inhibits the reaction [Fructose results in increased activity of MLXIPL protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of MMP9 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1,1-dimethylbutyl-1-deoxy-Delta(9)-THC co-treated with F2 protein] results in increased expression of MRC1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYH4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYH4 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYOG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Testosterone results in increased expression of MYOG protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of NFE2L2 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of NFE2L2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKB1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Mevinphos results in increased expression of NOS1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [cadmium acetate results in increased expression of NR4A1 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [bisphenol A results in increased expression of NR4A1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dimaprit results in increased expression of NTF3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Histamine results in increased expression of NTF3 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Neurotransmitter Agents results in increased expression of NTF3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of PGR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PGR mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of PINK1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [T-2 Toxin results in increased expression of PINK1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [PLD1 protein promotes the reaction [cobaltous chloride results in increased expression of PTGS2 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PLIN1 protein]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of PLIN2 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PNPLA2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of PNPLA6 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of PNPLA6 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of PPARGC1A protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GW9508 inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of PPARGC1A mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [GW9508 inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of PPARGC1A protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased phosphorylation of and results in increased activity of PRKACA protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in decreased expression of PRKACA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Copper Sulfate results in decreased expression of PRKACA protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased phosphorylation of PRKAR2A protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [resveratrol results in increased phosphorylation of PRKAR2A protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [PLD1 protein promotes the reaction [cobaltous chloride results in increased expression of PTGS2 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of PTGS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of PTGS2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [ADORA2B protein inhibits the reaction [Ethanol results in increased phosphorylation of RELA protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of SCARB1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid analog results in increased activity of SCT] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of SCT protein
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with TNF protein] results in decreased expression of SIRT1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in decreased expression of SIRT1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Oxygen co-treated with Glucose deficiency co-treated with 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxyglucopyranoside] results in increased expression of SLC2A3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SLC2A4 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin affects the splicing of SNAP25 exon]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide promotes the reaction [Acetaminophen results in decreased expression of and results in decreased activity of SOD1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Medroxyprogesterone Acetate results in increased expression of SOD2 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of STAR protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of STAR mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Lithium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [5-methyltetrahydrofolate inhibits the reaction [Palmitic Acid results in decreased phosphorylation of STK11 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [KNG1 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in decreased expression of KCNH2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in decreased expression of KCNJ2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN1A mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TGFB1 protein results in increased expression of CDKN2B mRNA]
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [Nicotine results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [HU 211 results in decreased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nicotine results in increased expression of TH mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of TH mRNA
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with TNF protein] results in decreased expression of SIRT1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dieldrin results in increased expression of TNF mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of TNF protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Terbutaline results in decreased expression of TNF mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Ammonia results in increased secretion of TNF protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [TNF protein promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 protein]] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNF mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Hydrogen Peroxide results in increased expression of TNFAIP6 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased abundance of TNFAIP6 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Melitten results in increased activity of TRPV1 protein] which results in increased transport of Calcium]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dipyridamole inhibits the reaction [Glucose results in decreased expression of TXN1 protein]]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [scoparone results in increased expression of TYR protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased activity of TYR protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of UCP1 protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of VASP protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [N(6)-benzoyl-cyclic AMP results in increased phosphorylation of VASP protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of BMP4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [WNT3A protein results in increased expression of CREB1 mRNA]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in increased expression of XIAP protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of XIAP mRNA
N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]
naltrindole inhibits the reaction [[Thiorphan binds to and results in decreased activity of MME protein] which results in increased susceptibility to Cocaine]
[naltrindole binds to and results in decreased activity of OPRD1 protein] which results in decreased susceptibility to 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole; Cannabidiol inhibits the reaction [naltrindole binds to and results in decreased activity of OPRD1 protein]; Dronabinol inhibits the reaction [naltrindole binds to and results in decreased activity of OPRD1 protein]; naltrindole binds to and results in decreased activity of OPRD1 protein; naltrindole inhibits the reaction [[Enkephalin, D-Penicillamine (2,5)- binds to and results in increased activity of OPRD1 protein] which results in increased susceptibility to Cocaine] [naltrindole binds to and results in decreased activity of OPRD1 protein] which results in increased susceptibility to Nicotine
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]]; neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]
FGFR2 protein inhibits the reaction [neferine results in decreased phosphorylation of AKT1 protein]; neferine promotes the reaction [Cisplatin results in decreased phosphorylation of AKT1 protein] neferine inhibits the reaction [Diethylnitrosamine results in increased expression of AKT1 mRNA]
neferine results in increased expression of ARPC5 protein FGFR2 protein inhibits the reaction [neferine results in increased expression of ARPC5 protein]; MIR374A mRNA inhibits the reaction [neferine results in increased expression of ARPC5 protein]
neferine inhibits the reaction [Diethylnitrosamine results in decreased expression of BAX mRNA]; neferine inhibits the reaction [Diethylnitrosamine results in decreased expression of BAX protein]
neferine inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 mRNA]; neferine inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 protein]
neferine results in increased cleavage of CASP3 protein FGFR2 protein inhibits the reaction [neferine results in increased cleavage of CASP3 protein]; MIR374A mRNA inhibits the reaction [neferine results in increased cleavage of CASP3 protein] neferine inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 mRNA]; neferine inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP3 protein]
neferine results in increased cleavage of CASP9 protein neferine inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP9 mRNA]; neferine inhibits the reaction [Diethylnitrosamine results in decreased expression of CASP9 protein] FGFR2 protein inhibits the reaction [neferine results in increased cleavage of CASP9 protein]; MIR374A mRNA inhibits the reaction [neferine results in increased cleavage of CASP9 protein]
neferine inhibits the reaction [Aluminum Chloride results in decreased expression of CAT protein]; neferine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]
neferine results in decreased expression of CCND1 protein FGFR2 protein inhibits the reaction [neferine results in decreased expression of CCND1 protein]; MIR374A mRNA inhibits the reaction [neferine results in decreased expression of CCND1 protein]
CYP2C8 protein results in increased metabolism of and results in decreased methylation of neferine CYP2C8 protein results in increased glutathionylation of neferine metabolite
CYP2D6 protein results in increased metabolism of and results in decreased methylation of neferine CYP2D6 protein results in increased glutathionylation of neferine metabolite
CYP3A4 protein results in increased glutathionylation of neferine metabolite [CYP3A4 protein co-treated with neferine] results in decreased abundance of Glutathione; Acetylcysteine inhibits the reaction [[CYP3A4 protein co-treated with neferine] results in decreased abundance of Glutathione]; Buthionine Sulfoximine promotes the reaction [[CYP3A4 protein co-treated with neferine] results in decreased abundance of Glutathione]; CYP3A4 protein results in increased metabolism of and results in decreased methylation of neferine; neferine promotes the reaction [[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione]
FGFR2 protein inhibits the reaction [neferine results in decreased expression of CCND1 protein]; FGFR2 protein inhibits the reaction [neferine results in decreased expression of MMP2 protein]; FGFR2 protein inhibits the reaction [neferine results in decreased expression of MMP9 protein]; FGFR2 protein inhibits the reaction [neferine results in decreased expression of VIM protein]; FGFR2 protein inhibits the reaction [neferine results in decreased phosphorylation of AKT1 protein]; FGFR2 protein inhibits the reaction [neferine results in decreased phosphorylation of MAPK1 protein]; FGFR2 protein inhibits the reaction [neferine results in decreased phosphorylation of MAPK3 protein]; FGFR2 protein inhibits the reaction [neferine results in decreased phosphorylation of PIK3R1 protein]; FGFR2 protein inhibits the reaction [neferine results in increased cleavage of CASP3 protein]; FGFR2 protein inhibits the reaction [neferine results in increased cleavage of CASP9 protein]; FGFR2 protein inhibits the reaction [neferine results in increased expression of ARPC5 protein]
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]] neferine results in increased expression of HMOX1 protein
neferine results in decreased phosphorylation of MAPK1 protein [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; FGFR2 protein inhibits the reaction [neferine results in decreased phosphorylation of MAPK1 protein]; neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]]; FGFR2 protein inhibits the reaction [neferine results in decreased phosphorylation of MAPK3 protein]; neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]
neferine results in decreased expression of MMP2 protein FGFR2 protein inhibits the reaction [neferine results in decreased expression of MMP2 protein]; MIR374A mRNA inhibits the reaction [neferine results in decreased expression of MMP2 protein]
FGFR2 protein inhibits the reaction [neferine results in decreased expression of MMP9 protein]; MIR374A mRNA inhibits the reaction [neferine results in decreased expression of MMP9 protein]
neferine inhibits the reaction [Diethylnitrosamine results in increased expression of PIK3R1 mRNA] neferine results in decreased phosphorylation of PIK3R1 protein FGFR2 protein inhibits the reaction [neferine results in decreased phosphorylation of PIK3R1 protein]
neferine inhibits the reaction [Aluminum Chloride results in increased expression of PTGS2 protein]; neferine inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 mRNA]; neferine inhibits the reaction [Diethylnitrosamine results in increased expression of PTGS2 protein]
neferine inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA mRNA]; neferine inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein]
FGFR2 protein inhibits the reaction [neferine results in decreased expression of VIM protein]; MIR374A mRNA inhibits the reaction [neferine results in decreased expression of VIM protein]
Nomifensine inhibits the reaction [Rotenone results in decreased expression of SLC6A3 protein] [Nomifensine results in decreased activity of SLC6A3 protein] which results in decreased susceptibility to 1-Methyl-4-phenylpyridinium; Nomifensine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]
norbinaltorphimine inhibits the reaction [Methamphetamine results in increased expression of DDIT3 mRNA]; norbinaltorphimine inhibits the reaction [Methamphetamine results in increased expression of DDIT3 protein]
norbinaltorphimine binds to and results in decreased activity of OPRK1 protein norbinaltorphimine binds to and results in decreased activity of OPRK1 protein; norbinaltorphimine inhibits the reaction [Dynorphins binds to and results in increased activity of OPRK1 protein]; norbinaltorphimine inhibits the reaction [naloxone benzoylhydrazone binds to and results in increased activity of OPRK1 protein]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]
norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]
[[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; [ALDH2 protein affects the abundance of Tetrahydropapaveroline] which affects the susceptibility to Cocaine; [CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline
Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Tetrahydropapaveroline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Papaverine inhibits the reaction [Isoproterenol affects the localization of LIPE protein]; Papaverine inhibits the reaction [Isoproterenol results in increased activity of LIPE protein]
Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Papaverine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]
PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to alachlor]; PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to Antimycin A]; PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to mesoxalonitrile]; PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to pyridaben]; PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to Rotenone] PK 11195 results in decreased expression of BCL2 PK 11195 results in decreased expression of BCL2 protein
[PK 11195 co-treated with RXRA] results in increased activity of NR1I2 protein; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein] PK 11195 results in increased activity of NR1I2 protein
1,5-benzothiazepine analog inhibits the reaction [PK 11195 results in decreased activity of NR1I3 protein]; 4-nonylphenol inhibits the reaction [PK 11195 results in decreased activity of NR1I3 protein]; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [PK 11195 results in decreased activity of NR1I3 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine promotes the reaction [PK 11195 results in decreased activity of NR1I3 protein]; [4-ethylphenol co-treated with PK 11195] results in decreased activity of NR1I3 protein alternative form; [Diphenhydramine co-treated with PK 11195] binds to and results in increased activity of NR1I3 protein alternative form; [Ketoconazole co-treated with PK 11195] results in decreased activity of NR1I3 protein alternative form; [Loperamide co-treated with PK 11195] results in decreased activity of NR1I3 protein alternative form; PK 11195 binds to and results in decreased activity of NR1I3 protein; PK 11195 binds to and results in increased activity of NR1I3 protein mutant form; PK 11195 inhibits the reaction [GRIP1 protein binds to NR1I3 protein]; PK 11195 inhibits the reaction [NR1I3 protein binds to NCOA1 protein]; PK 11195 inhibits the reaction [SRC protein binds to NR1I3 protein]; PK 11195 promotes the reaction [NR1I3 protein binds to NCOR1 protein]; PK 11195 results in decreased susceptibility to [3-pentadecylphenol binds to and results in increased activity of NR1I3 protein alternative form]; PK 11195 results in decreased susceptibility to [4,4'-bisphenol F binds to and results in increased activity of NR1I3 protein alternative form]; PK 11195 results in decreased susceptibility to [4-nonylphenol binds to and results in increased activity of NR1I3 protein alternative form]; PK 11195 results in decreased susceptibility to [resveratrol binds to and results in increased activity of NR1I3 protein alternative form]; PK 11195 results in increased susceptibility to [Terphenyl Compounds binds to and results in increased activity of NR1I3 protein alternative form]
[PK 11195 co-treated with RXRA] results in increased activity of NR1I2 protein; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]
PK 11195 binds to TSPO protein TSPO protein affects the susceptibility to PK 11195 9,10-Dimethyl-1,2-benzanthracene inhibits the reaction [PK 11195 binds to TSPO protein]
[Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [roxadustat results in increased activity of HIF1A protein] roxadustat promotes the reaction [Hyaluronic Acid results in increased expression of HIF1A protein]
Tubocurarine promotes the reaction [Dichlorvos results in increased phosphorylation of ACHE protein]; Tubocurarine promotes the reaction [haloxon results in increased phosphorylation of ACHE protein]; Tubocurarine promotes the reaction [Paraoxon results in increased phosphorylation of ACHE protein]
Tubocurarine inhibits the reaction [[Nicotine results in increased metabolism of APP protein] which results in increased secretion of APP protein modified form]; Tubocurarine inhibits the reaction [Nicotine results in increased metabolism of APP protein]
Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA2 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]]
Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]; Tubocurarine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA3 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]]; Tubocurarine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]
Tubocurarine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]]; Tubocurarine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]
Tubocurarine binds to and results in decreased activity of CHRNA7 protein; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]; Tubocurarine inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]
Tubocurarine inhibits the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Ethinyl Estradiol promotes the reaction [Acetylcholine affects the activity of [CHRNA4 protein binds to CHRNB2 protein]]]; Tubocurarine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein] Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA2 protein]]; Tubocurarine inhibits the reaction [Acetylcholine binds to and results in increased activity of [CHRNB2 protein binds to CHRNA3 protein]]
Tubocurarine inhibits the reaction [Acetylcholine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]]; Tubocurarine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]] Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]]; Tubocurarine promotes the reaction [Acetylcholine binds to and results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]]; Tubocurarine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]
Tubocurarine results in increased expression of CNTN1 mRNA Tubocurarine inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA] Tubocurarine results in decreased expression of CNTN1 mRNA
Tubocurarine results in decreased expression of GOLGA4 mRNA Tubocurarine inhibits the reaction [Nicotine results in increased expression of GOLGA4 mRNA]
Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 mRNA]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]]
Tubocurarine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 protein]
Tubocurarine results in decreased expression of POU5F1 mRNA Tubocurarine inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA]
Tubocurarine inhibits the reaction [PTMA protein results in decreased expression of BCL2]; Tubocurarine inhibits the reaction [PTMA protein results in increased expression of FAS]
browse the term
